Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.

Cancers (Basel) · 2021 · PMC7967147 · PMID 33803335

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although patients with no prior CPI showed a trend for more favorable progression-free survival relative to patients with prior CPI, the improvement in the 1-year OS did not reach the statistical threshold in this heavily treated patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.